March 9, 2026—Agilent Technologies has entered into a definitive agreement to acquire Biocare Medical in an all-cash transaction valued at $950 million. Biocare has achieved annual double-digit revenue and profit growth since 2021 and generated more than $90 million in revenue in 2025. The deal is expected to increase Agilent’s earnings per share within about a year after the transaction is completed.
Biocare’s portfolio includes immunohistochemistry, in situ hybridization, and fluorescence in situ hybridization solutions in oncology and broader clinical pathology. The transaction is expected to close no later than Agilent’s fourth fiscal quarter of 2026, subject to customary closing conditions, including receipt of regulatory approvals. Biocare will become part of Agilent’s life sciences and diagnostics markets group upon closing.
“Over the past several years our teams have built something special—advancing diagnostic technologies, expanding global reach, and delivering solutions that help laboratories generate answers for patients every day,” John Steel, SVP and general manager of Empire Genomics, said in a March 9 LinkedIn post. “This next chapter gives us the opportunity,” he continued, “to scale that impact even further with Agilent’s global infrastructure and scientific leadership.” Empire Genomics is a subsidiary of Biocare.